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Abstract: Compliance and relapse are major issues in the treatment of psychotic disorders. 
About 50% of subjects with schizophrenia do not comply with treatment and relapse rates of 
65% are reported after one year and 80% after two years. Drug treatments are effective against 
psychotic symptoms, but cannot promote functional recovery or prevent relapses when prescribed 
alone. The factors inﬂ  uencing compliance include side effects and the patients’ awareness of 
their illness. Psychosocial interventions, cognitive remediation and psychotherapy have been 
proposed as adjuvant treatments to increase compliance and to decrease the rate of relapse. 
Most of these interventions have been shown to increase compliance and to decrease the rate 
of relapse, but the most robust results have been achieved with cognitive behavioral therapy.
Keywords: schizophrenia, psychotic disorders, compliance, antipsychotics, cognitive reme-
diation
Introduction
Psychotic disorders and schizophrenia are disabling conditions characterized by 
positive symptoms, negative symptoms, and cognitive impairments. Most individuals 
with schizophrenia have a poor long-term outcome resulting in personal suffering and 
psychosocial disabilities including impaired interpersonal and vocational skills.
The use of antipsychotic medication to treat schizophrenia is well established. 
These drugs have been shown to be effective during the acute phase and for preventing 
relapse (Kennedy et al 2000; Quraishi and David 2000); Kisling (1994) argued that if 
patients complied fully with their medication, relapse rates would fall to about 15% 
(almost 50% of patients relapse within a year of achieving remission). Noncompli-
ance is common throughout medicine, but some aspects of schizophrenia may make 
it particularly difﬁ  cult for patients to accept their treatment. Although antipsychotic 
medication decreases symptoms, other issues may temper these beneﬁ  cial effects, 
resulting in poor compliance and high rates of relapse. These issues include the side 
effects of antipsychotic drugs (such as weight gain, parkinsonism), and poor func-
tional recovery following psychotic episodes. The rate of noncompliance is difﬁ  cult to 
assessed, but has been estimated at 25%–41% (Jeste et al 2003). Hogarty and colleagues 
(1997) demonstrated that the relapse rate increases from 40% to 65% after one year 
and to 80% after two years if medication is discontinued. However, if psychosocial 
treatment is given in addition to maintenance drug treatment, the relapse rate may be 
up to 50% lower than that for drug treatment and standard care. Factors associated 
with noncompliance include poor insight, negative attitude to medication, a history 
of noncompliance, substance abuse, short duration of illness and a poor therapeutic 
alliance (Jeste et al 2003).
Individuals suffering from psychosis tend to have impaired social functioning 
(Erickson et al 1989; Grant et al 2001), quality of life (Priebe et al 2000; Addington 
et al 2003a; Addington 2003b), cognitive and occupational functioning, even if they 
display clinical recovery (Penn et al 2005). These rate-limiting factors should be Neuropsychiatric Disease and Treatment 2007:3(4) 512
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considered as therapeutic targets for improving psychoso-
cial outcome and increasing the readiness of people with 
schizophrenia to undergo rehabilitation. Baseline attitudes to 
treatment and motivational and training variables also affect 
remediation (Fiszdom et al 2005). Several programs deal-
ing with these aspects have been developed and the term of 
“compliance therapy” is sometimes used (Kemp et al 1996, 
1998). Compliance therapy includes cognitive behavioural 
therapy, psychoeducation and remediation, with the aim of 
providing information about the illness and side effects, and 
improving cognitive and psychosocial functioning.
We review here previous studies dealing with compli-
ance in schizophrenia and psychotic disorders. The articles 
were selected from the MEDLINE and PubMed databases, 
using the following terms: (1) remediation, (2) rehabilita-
tion, (3) psychosis, (4) antipsychotics, and (5) psychosocial 
treatment.
Antipsychotic medication 
and attitudes to treatment
The patient’s attitude to medication is a major issue in 
determining the outcome. This attitude to drug may reﬂ  ect 
compliance. Relapse rates have been shown to be up to ﬁ  ve 
times higher in noncompliant than in compliant subjects, 
resulting in signiﬁ  cantly higher costs for these patients 
and for society (Robinson et al 1999). Several studies have 
investigated the possible relationship between compliance 
and type of antipsychotic medication (Kane et al 1985; Lacro 
et al 2002). Some have suggested that the use of atypical an-
tipsychotic drugs may be associated with fewer side effects, 
better compliance and a lower rate of relapse. The newer 
antipsychotic drugs efﬁ  ciently attenuate the symptoms of 
schizophrenia without causing dysphoria and motor side 
effects. This higher tolerability and efﬁ  cacy may lead to 
more positive attitudes to drug treatment in schizophrenic 
patients taking second-generation antipsychotic drugs than 
in patients taking ﬁ  rst-generation antipsychotic drugs (Day 
et al 2005). The speciﬁ  city of care associated with some treat-
ments may be beneﬁ  cial to patients. Marder and colleagues 
(1996) showed in their review that periodic visits for blood 
monitoring, which are obligatory for patients on clozapine, 
improved the therapeutic alliance, making it easier for the 
clinician to monitor compliance.
The question of the relationship between adverse effects 
and compliance with medication is highly complex. Some 
studies have reported a signiﬁ  cant relationship between vari-
ous adverse effects and noncompliance, whereas others do 
not. According to Kampman and colleagues (2002), patients’ 
predictions concerning their compliance depend on the harm-
ful side effects they experience at the acute phase of psycho-
sis. Extra-pyramidal effects are most frequently considered 
anticholinergic and other adverse effects are also linked 
to compliance. According to Freudenreich and colleagues 
(2004), extra-pyramidal symptoms are not the primary factor 
determining attitudes to treatments. These authors studied 
the relationship between drug attitude inventory (DAI scale) 
score and psychopathology, insight, extra-pyramidal symp-
toms, level of functioning and type of antipsychotic drug 
in 81 schizophrenic outpatients. Their results suggest that 
patients who recognize adverse effects of therapeutic drugs 
may actually have a more positive attitude. 
It has also been suggested that personal characteristics 
such as attitude to health and illness, may be critical in 
determining attitudes to medication (Jeste et al 2003). 
These factors might reduce the importance of medication-
related side effects in determining treatment compliance. 
Indeed, it has been shown that distress due to side effects 
is not necessarily linked to noncompliance in outpatients 
with schizophrenia (Weiden et al 1991). In addition, 
no significant difference in compliance was found be-
tween depot, first- and second-generation antipsychotics 
(Rittmannsberger et al 2004). Schizophrenic subjects do 
not perceive side effects and symptoms as independent 
(Carrrick et al 2004). In a review of the literature concern-
ing side effects and compliance, Lacro and colleagues 
(2002) reported that subjective response to medication 
affects both compliance and the risk of relapse. They also 
found that noncompliance was associated with a poorer 
therapeutic alliance. These results were confirmed by 
Rettenbacher and colleagues (2004), in both inpatients 
and outpatients. These authors demonstrated a positive 
correlation between compliance and the patients’ impres-
sion that the drug had a positive effect on the illness. They 
therefore stressed the need to include patients and their 
relatives in the treatment decision process, to increase 
treatment compliance. Perkins and colleagues (1990) 
proposed a model in which compliance with treatment is 
determined by the patients’ assessment of the perceived 
benefits of treatment and the risks of illness versus the 
costs of treatment, including adverse effects. Patients who 
believe that the risks of treatment outweigh the benefits 
are likely to stop taking their medication. Patients who 
recognize the therapeutic effects of their medication may 
therefore have a more positive attitude to treatment.
Thus, side effects do not seem to be the main predictor 
of compliance: attention should therefore be paid to the Neuropsychiatric Disease and Treatment 2007:3(4) 513
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patients’ subjective feelings about treatment, including 
the recognition of positive and negative therapeutic 
effects in particular.
Psychological interventions
Pharmacological treatments are the ﬁ  rst-line treatment for 
schizophrenia, but adjuvant treatments are also required to 
achieve functional recovery or to prevent relapse because 
antipsychotic drugs may not be sufﬁ  ciently effective and 
noncompliance is a common problem (Ratakonda et al 
1997). Psychotic disorders and schizophrenia should there-
fore be treated with a combination of drugs, psychological 
treatment and the rehabilitation of cognitive disorders and 
social skills. Several approaches have been developed includ-
ing supportive therapy, integrated psychological treatment 
and social skills training. Interest in psychoeducation and 
remediation has recently increased (Spaulding et al 1999; 
Wikes et al 1999; Penadés et al 2002; Addington et al 2004; 
Byerly et al 2005). Educational interventions aim to provide 
patients with information about their illness and medication, 
with a view to increasing their understanding and promot-
ing compliance. Penadés and colleagues (2002) showed 
that clinically orientated cognitive rehabilitation treatments 
seem to improve not only cognitive functioning and other 
functional aspects related to the illness. They compared 24 
schizophrenia patients with cognitive impairment and 10 
schizophrenia patients without cognitive impairment on 
integrated psychological treatment. They found a relationship 
between neuropsychological improvements and a greater 
autonomy and social functioning. Some studies have reported 
a positive correlation between executive functions, as evalu-
ated with the Wisconsin Card Sorting Test and social com-
petence (Spaulding et al 1999), or between verbal memory 
performance and psychosocial skill acquisition (Spaulding 
et al 1999; Wikes et al 1999). In 1996, Marder and colleagues 
randomly assigned eighty patients with schizophrenia to two 
groups, receiving either social skills training or supportive 
group therapy. Rates of psychotic exacerbation and Social 
Adjustment Scale scores were monitored. Signiﬁ  cant main 
effects were identiﬁ  ed, showing that social skills training 
was significantly more effective than supportive group 
therapy and signiﬁ  cant interactions between psychosocial 
treatment and drug treatment were identiﬁ  ed. However, 
the improvements observed were modest and conﬁ  ned to 
certain subgroups of patients. McPherson and colleagues 
(1996) compared one educational session with three educa-
tional sessions. They found that both regimes improved the 
patients’ knowledge about their medication but that three 
sessions of education gave signiﬁ  cantly better results than 
one educational session during follow-up.
Four studies by Addington and colleagues (2001, 2003a, 
2003b, 2004) examined the results of the Calgary Early 
Psychosis Program (offering a wide range of psychosocial 
interventions targeting the family, drug therapy, social skills) in 
patients with nonaffective ﬁ  rst-episode psychosis (examining 
social functioning and quality of life over the course of one 
year). No effect on relapse rate was identiﬁ  ed in any of these 
studies. However, only one of these studies reported a better 
quality of life and social functioning in patients receiving such 
interventions (Addington et al 2003b). One study reported 
a decrease in the use hallucinogens, cannabis and alcohol 
in heavy users (Addington et al 2001) and another reported 
improvements in depression (Addington et al 2003a). 
Computer-assisted cognitive enhancement therapy has 
been shown to modify cognitive style and social cogni-
tion in 121 schizophrenia patients (Hogarty et al 2004). 
The observed relapse rate was low in this study (10% after 
two years), and was signiﬁ  cantly lower in the subgroup of 
patients with an IQ of 80 or higher. Finally, Byerly and 
colleagues (2005) examined the effect of a cognitive and 
psycho-educational approach in an open trial including 30 
subjects with schizophrenia and schizoaffective disorders. 
Symptoms, insight, and attitude to medication did not change 
signiﬁ  cantly during the study.
Most studies have demonstrated that cognitive deﬁ  cits 
and related behavior are improved in patients suffering 
from schizophrenia, provided with sufﬁ  cient rehabilitation 
(Spaulding et al 1999; Wikes et al 1999; Penadés et al 2002; 
Addington et al 2004). Recommendations for a speciﬁ  c 
psychosocial intervention in schizophrenia are probably best 
made on the basis of patient characteristics: intelligence, 
duration of illness, and phase of illness (Hogarty et al 2004). 
A meta-analysis of randomised controlled trials of social 
skills training and cognitive remediation provided no clear 
evidence of any beneﬁ  ts of social skills training on the global 
adjustment of relapse rate, social functioning, quality of life 
or treatment compliance (Pilling et al 2002).
Cognitive behavioral therapy 
(CBT) and other psychological 
interventions
Most studies on CBT in schizophrenia have assessed the 
efﬁ  cacy of this approach and its effects on the symptoms of 
schizophrenia (see Turkington et al 2006). However, few Neuropsychiatric Disease and Treatment 2007:3(4) 514
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studies have tested whether CBT is more beneﬁ  cial than 
treatment as usual (TAU) in terms of relapse and rehospital-
ization rates. Some studies have shown CBT to be of beneﬁ  t 
in the treatment of positive (Tarrier et al 1998) and negative 
schizophrenia symptoms (Sensky et al 2000). A prospective, 
multicentre, randomised controlled trial, with rater blind-
ing and an 18-month follow-up period was conducted by 
Tarrier and colleagues (1998). In this study, CBT was found 
to be signiﬁ  cantly more effective than TAU for attenuating 
symptoms and reducing relapse and rehospitalization rates. 
Other studies have also reported CBT to be signiﬁ  cantly more 
effective than TAU in psychotic subjects suffering from an 
acute episode (Lewis et al 2002; Tarrier et al 2004; Startup 
et al 2004) or chronic illness (Turkington et al 2002; Durham 
et al 2003; Rector et al 2003; Trower et al 2004). Similar 
improvements were also observed when the patients’ insight 
was assessed (Rathod et al 2005; Valmaggia et al 2005). The 
patients’ insight into compliance and its implications were 
signiﬁ  cantly better in CBT group than in the TAU group, but 
this difference was not maintained at follow-up (Rathod et al 
2005; Valmaggia et al 2005). Functional CBT (FCBT) has 
recently been developed as a novel approach for the treatment 
of psychotic symptoms. This technique was developed to ex-
tend the effects of CBT beyond symptom reduction, focusing 
on symptom interventions, working on functional goals. The 
therapeutic alliance and the patients’ motivation are thought 
to be improved by linking interventions to life goals. In a pilot 
study, Carter and colleagues (2005) compared FCBT with 
psychoeducation (PE) in 30 outpatients with schizophrenia. 
Both treatments consisted of weekly one-hour individual 
sessions for a total of 16 weeks. FCBT was signiﬁ  cantly 
correlated with greater attenuation of positive symptoms and 
improvements in functioning (60% for FCBT versus 31% for 
PE). Another study compared PE with CBT (Bechdolf et al 
2005). The CBT group had signiﬁ  cantly lower rehospitaliza-
tion rates and higher levels of compliance with medication, 
persisting for more than two years. Finally, Zimmermann and 
colleagues (2005) performed a meta-analysis on the efﬁ  cacy 
of CBT in schizophrenia. This meta-analysis supported the 
general conclusion that CBT is a promising approach for the 
adjuvant treatment of positive symptoms in schizophrenia. 
Moreover, the therapeutic effects of CBT persist during fol-
low-up, suggesting that CBT has long-term effects. Similar 
conclusions were drawn by Butler and colleagues (2006) in 
a review of meta-analyses. A large effect on the decrease in 
psychotic symptoms has been found and long-term follow-up 
has shown the maintenance of gains and even an increase in 
their magnitude. However, both authors highlighted a number 
of variables that have not been speciﬁ  cally examined such as 
therapeutic alliance and neuropsychological deﬁ  cits.
Other psychosocial treatments may be effective at 
preventing schizophrenia relapse. Personal therapy has a 
pervasive effect on social adjustment, which continues to 
improve three years of after discharge (Hogarty et al 1997b). 
However, personal therapy increases the rate of psychotic 
relapse for independent patients living away from their fami-
lies (Hogarty et al 1997a). The intervention of the family has 
also been identiﬁ  ed as important for preventing relapse and 
readmission (Pilling et al 2002).
Insight
According to Kemp and colleagues (1996, 1998), three 
dimensions deﬁ  ne insight: acknowledgment of the psychi-
atric disease, ability to recognize psychiatric symptoms, 
and compliance with treatment. The lack of insight, or un-
awareness of illness in people with schizophrenia has been 
recognized as a medical condition: anosognosia.
A Dutch study has indicated that 80% of schizophrenic 
patients are aware of their diagnosis (Van Meer et al 1997). 
Only 20% of these subjects sought this information from their 
psychiatrist, the others received this information from their 
doctor without asking for it. In a French study, more than 
60% of patients declared that they knew the name of their 
illness and were able to talk about schizophrenic or psychotic 
disorders (Ferreri et al 2000). Several studies have evaluated 
the level of comprehension of individuals with schizophrenic 
disorders. Wirshing and colleagues (2002) showed that only 
10% of people suffering from schizophrenia were able to 
understand this from their ﬁ  rst interview with the psychiatrist. 
A second explanation from the doctor was required in 53% 
of the cases. This study showed that the level of comprehen-
sion is correlated with the conceptual disorganization item 
of the BPRS scale.
Several specialists regard the question of insight as a 
major factor, enabling schizophrenia patients to take an 
active role in managing their symptoms and problems. 
Previous studies focusing on insight or self-awareness 
in schizophrenia have suggested that this cognitive di-
mension may have nosological value (Rittmannsberger 
et al 2004). The results obtained suggest that severe self-
awareness deficits are a prevalent feature of schizophrenia 
(Smith et al 2004). The lack of insight of schizophrenia 
patients is an important clinical issue. In a reference 
study of about 35 male forensic patients suffering from 
chronic schizophrenia, only 51% believed that they were 
suffering from a mental disorder (Goodman et al 2005). Neuropsychiatric Disease and Treatment 2007:3(4) 515
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In this study, a similar proportion reported awareness of 
a need for medication and correctly attributed symptoms 
to illness. This study also showed that poorer insight was 
correlated with a higher frequency of violent events. 
Amador and colleagues (1994) suggested that the lack of 
insight has two components: unawareness of illness and 
incorrect attributions of the causes of illness. Insight into 
illness and greater recognition of symptoms, severity of 
illness and functioning are predictors of a more favorable 
outcome in schizophrenia.
Symptom awareness deﬁ  cits are common in schizophre-
nia and have been associated with poor treatment compli-
ance (Davis et al 2004). Several studies have reported that 
individuals with severe negative symptoms tend to have 
the poorest insight (Amador et al 1994; Collins et al 1997; 
Schwartz et al 1998; Carroll et al 1999). In all these studies, 
impaired insight was considered to be an important factor 
contributing to poor treatment response and outcome in 
schizophrenia. Droulout and colleagues (2003) studied the 
relationships between insight and compliance with medi-
cation in subjects with psychosis. They demonstrated that 
compliance with medication is associated with the level of 
insight, independently of the patients’ other demographic 
and clinical characteristics. This association between low-
level insight and poor compliance with medication has been 
conﬁ  rmed in several studies.
Quality of life
The question of the quality of life of individuals suffering 
from schizophrenia remains a little-studied issue. Awad and 
colleagues (2004) developed a conceptual model, suggesting 
that the major determinants of quality of life in schizophrenia 
are symptom severity, level of psychosocial functioning, and 
the presence of medication side effects. This model also sug-
gests that quality of life may be inﬂ  uenced by the individual’s 
subjective response to neuroleptic medication.
Some previous reports have suggested that insight has 
a major impact on quality of life scores (Atkinson et al 
1997). The evaluation of quality of life made by individuals 
with schizophrenia may be inﬂ  uenced by the presence of 
psychotic symptoms and by adaptation to the adverse social 
circumstances that they frequently experience. In several 
epidemiological studies, schizophrenic patients with poor 
insight, particularly those who displayed a lack of awareness 
of the consequences of the illness, were found to be more 
socially isolated and to have poorer psychosocial functioning 
(Amador et al 1994). According to Browne and colleagues 
(2005), there is no signiﬁ  cant relationship between quality 
of life and the level of insight. These authors reported a 
direct link between the development of treatment strategies 
to alleviate neuroleptic-induced dysphoria and the beneﬁ  ts 
of rehabilitation programmes for improving quality of life. 
In everyday life, the question of quality of life is associated 
with the problem of comorbidity. For example, nicotine 
problems are very frequently diagnosed by psychiatrists in 
people suffering from schizophrenia (Montoya et al 2005). 
Patients with such nicotine problems display poorer treatment 
compliance than their counterparts without such problems 
(Hudson et al 2004). In a sample of 1843 patients followed by 
psychiatrist, 16.6% were reported to have a current nicotine 
problem. This study suggests that psychiatric patients who 
smoke have more clinical and psychosocial stressors and 
more severe psychiatric problems than those who do not 
smoke (Montoya et al 2005). Little is known about the extent 
to which patients suffering from schizophrenia are preoc-
cupied by their health and how often they request assistance 
to give up smoking.
Therapeutic alliance
In many studies, the therapeutic alliance has been associated 
with compliance (Fenton et al 1997; Kampman et al 1999; 
Lacro et al 2002; Day et al 2005). More and more studies are 
now examining the subjective reasons for which patients are 
willing or reluctant to take medication. According to Lofﬂ  er 
et al (2003), the quality of relationships with clinicians dur-
ing acute admissions appears to be a major determinant of 
patients’ attitudes to treatment and compliance with medica-
tion. They assessed attitudes to treatment and self-reported 
compliance with medication in 28 inpatients and showed 
that a poor relationship with the prescriber, a feeling of 
being coerced during admission and a low level of insight 
were predictive of a negative attitude to treatment. Similarly, 
two other studies have shown that feelings of coercion were 
associated with a tendency to reject psychiatric services 
(Rogers et al 1993; Lidz et al 2000). In a study of compliance 
in outpatients, Rittmannsberger et al (2004) found that regular 
visits to a psychiatrist were correlated with good compliance. 
According to these authors, not visiting a psychiatrist could 
be seen as just another aspect of noncompliance. They also 
suggested that visiting a psychiatrist may protect against 
noncompliance. According to Davis et al (2004), neurocog-
nition may be predictive of perceived therapeutic alliance in 
people with schizophrenia. These authors showed in a sample 
of 24 patients with schizophrenia spectrum disorders, that 
poorer performance in verbal memory tests was signiﬁ  cantly 
related to client reporting of a strong alliance, whereas better Neuropsychiatric Disease and Treatment 2007:3(4) 516
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performance in visual spatial reasoning tests was signiﬁ  cantly 
related to therapist reporting of a strong alliance.
Conclusion
Published studies on compliance have highlighted the impor-
tance of assessing the factors inﬂ  uencing compliance at an 
early stage of the disease process. Side effects of medication 
and the patient’s awareness of their illness are major issues 
in the treatment of psychotic disorders because of the high 
rate of relapse. 
The use of atypical antipsychotic drugs, in addition to 
reducing schizophrenic symptoms, may also be associated 
with fewer side effects. The higher tolerability and efﬁ  cacy 
of these drugs may lead to more positive attitudes to drug 
treatment in schizophrenic patients taking second-generation 
antipsychotic drugs.
Psychosocial interventions, cognitive remediation and 
psychotherapy have all been proposed as adjuvant treatments 
for increasing compliance, but the most robust results have 
been achieved with cognitive behavioral therapy.
Thus, reducing the side effects of the antipsychotic medi-
cation associated with psychological interventions seems to 
be a major challenge in efforts to improve compliance.
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